MCI
Conditions
Brief summary
The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.
Detailed description
Older people suffering from Type 2 Diabetes Mellitus possess a major risk for age related cognitive dysfunction and dementia, mainly due to vascular complications. SGLT2 inhibitors and DPP4 inhibitors are antidiabetic medications, have shown promise not only in glycemic control but also in potentially mitigating cognitive decline and depressive symptoms.
Interventions
DRUGSGLT2 Is+METFORMIN
Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months
DRUGDPP4 Is+metformin
Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months
DRUGControl group
patients administered their standard of care without any changes for the past 6 months
Sponsors
Beni-Suef University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- The study participants should meet the following inclusion criteria: 1. T2DM adult subjects (\>55 years old) will be eligible to participate. 2. Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.
Exclusion criteria
1- Those with type1 diabetes or ketoacidosis, insulin therapy, end organ failure as chronic renal failure, liver, and heart failure, previous history of pancreatitis, history of Alzheimer's disease or any brain insult, and finally pregnant or lactating females will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MCI | Day 1 | Changes in Montreal Cognitive Assessment (MoCA) score |
| Depression | Day 1 | Changes in Patient Health Questionnaire-9 (PHQ-9) score |
Countries
Egypt
Outcome results
None listed